Unknown

Dataset Information

0

Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes.


ABSTRACT: Parainfluenza virus type 3 (PIV-3) can cause severe respiratory illness among hematopoietic cell transplantation (HCT) recipients. Factors associated with PIV-3-specific Ab level, and the association between PIV-3 Ab levels and clinical outcomes in HCT recipients who acquire PIV-3 infection, are unknown. We evaluated PIV-3-specific hemagglutination inhibition Ab levels and clinical outcomes among 172 patients with PIV-3 infection following HCT. In a multivariable linear regression model, high post-transplantation Ab levels were independently associated with higher pre-transplantation recipient titer (mean difference 0.38 (95% confidence interval (CI), 0.26, 0.50), P<0.001). Significant associations between pre-HCT Ab titers in both patients and donors and occurrence of lower respiratory tract disease (LRD) after HCT were not observed. In conclusion, low pre-transplantation titers are associated with low Ab levels after HCT. The relationship between PIV-3 Ab levels and outcomes remain uncertain. Further study is needed to prospectively evaluate the dynamics of PIV-3-specific Ab responses and the relative contribution of PIV-3-specific Ab to protection from infection acquisition and progression to LRD.

SUBMITTER: Seo S 

PROVIDER: S-EPMC4332699 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes.

Seo S S   Xie H H   Karron R A RA   Thumar B B   Englund J A JA   Leisenring W M WM   Stevens-Ayers T T   Boeckh M M   Campbell A P AP  

Bone marrow transplantation 20140630 9


Parainfluenza virus type 3 (PIV-3) can cause severe respiratory illness among hematopoietic cell transplantation (HCT) recipients. Factors associated with PIV-3-specific Ab level, and the association between PIV-3 Ab levels and clinical outcomes in HCT recipients who acquire PIV-3 infection, are unknown. We evaluated PIV-3-specific hemagglutination inhibition Ab levels and clinical outcomes among 172 patients with PIV-3 infection following HCT. In a multivariable linear regression model, high po  ...[more]

Similar Datasets

| S-EPMC7698973 | biostudies-literature
| S-EPMC3390201 | biostudies-literature
| S-EPMC6546901 | biostudies-literature
| S-EPMC5397711 | biostudies-literature
| S-EPMC4684719 | biostudies-literature
| S-EPMC8477622 | biostudies-literature
| S-EPMC4559843 | biostudies-literature
| S-EPMC5682195 | biostudies-literature
| S-EPMC7459042 | biostudies-literature
| S-EPMC7710331 | biostudies-literature